Finance

Lists
4506:TYO
Sumitomo Pharma Co Ltd
JP¥1 411,50
-3,65%
(-53,50) 1D
21 Aug., 15:30:00 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4506...
Open
JP¥1 435
High
JP¥1 450
Low
JP¥1 400
Mkt. cap
634,05 mjd
Avg. vol.
3,96 m
Volume
3,65 m
P/E ratio
5,04
52-wk high
JP¥3 288
52-wk low
JP¥1 188
EPS
JPÂ¥280
Shares outstanding
397,30 m
No. of employees
3 k
Open
JP¥1 435
High
JP¥1 450
Low
JP¥1 400
Mkt. cap
634,05 mjd
Avg. vol.
3,96 m
Volume
3,65 m
P/E ratio
5,04
52-wk high
JP¥3 288
52-wk low
JP¥1 188
EPS
JPÂ¥280
Shares outstanding
397,30 m
No. of employees
3 k
Profile
Sumitomo Pharma Company Limited is a Japanese multinational pharmaceutical company. The company is focused on oncology, psychiatry, neurology, women's health issues, urological diseases among other areas. Its headquarters are located in Chuo-ku, Osaka. Wikipedia
About Sumitomo Pharma Co Ltd
CEO-
Employees3,12 k
Founded14 Mei 1897
HeadquartersOsaka, Osaka-prefektuur, Japan
SectorPharmaceutical industry
Websitesumitomo-pharma.co.jp
Last report
31 Jul. 2026
Fiscal period
Q1 2027
EPS / Est. (JPY)
- / -
Revenue / Est. (JPY)
129,50 mjd / 114,10 mjd
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
119,12 mjd
120,62 mjd
105,55 mjd
129,50 mjd
Cost of goods sold
45,59 mjd
55,44 mjd
51,26 mjd
61,41 mjd
Cost of revenue
45,59 mjd
55,44 mjd
51,26 mjd
61,41 mjd
Research and development expenses
9,35 mjd
10,35 mjd
16,12 mjd
11,43 mjd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
40,90 mjd
42,94 mjd
43,52 mjd
39,24 mjd
Operating expense
-1,04 mjd
52,19 mjd
110,09 mjd
50,33 mjd
Total operating expenses
44,55 mjd
107,63 mjd
161,36 mjd
111,74 mjd
Operating income
74,57 mjd
13,00 mjd
-55,81 mjd
17,75 mjd
Other non operating income
-
-
-1,64 mjd
-
EBT including unusual items
80,87 mjd
8,74 mjd
-1,20 mjd
18,30 mjd
EBT excluding unusual items
80,87 mjd
8,74 mjd
-51,00 mjd
18,30 mjd
Income tax expense
-6,78 mjd
-80,00 m
-383,00 m
1,30 mjd
Effective tax rate
-8,39%
-0,92%
32,05%
7,09%
Other operating expenses
-51,30 mjd
-1,10 mjd
50,45 mjd
-337,00 m
Net income
87,65 mjd
8,82 mjd
-812,00 m
17,00 mjd
Net profit margin
73,58%
7,31%
-0,77%
13,13%
Earnings per share
-
-
-
-
Interest and investment income
5,11 mjd
258,00 m
4,64 mjd
2,20 mjd
Interest expense
-
-5,14 mjd
-
-2,09 mjd
Net interest expenses
5,11 mjd
-4,88 mjd
4,64 mjd
107,00 m
Depreciation and amortization charges
-
-
-
-
EBITDA
79,85 mjd
18,32 mjd
-52,48 mjd
22,65 mjd
Gain or loss from assets sale
1,96 mjd
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme